Drug intelligence / Profile preview

EMP502-Dx

Development stage: Preclinical
Lead developer: Empiriko
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

EMP502-Dx is a research-stage diagnostic radiotracer being developed by Empiriko for the imaging of ovarian cancer. It consists of a gallium-68 (68Ga) radioisotope conjugated to a folate receptor-alpha (FRα) targeting ligand using Empiriko's proprietary Radioactive Carrier Vehicle (RCV) technology. Designed as a companion diagnostic, EMP502-Dx enables the identification of patients with FRα-positive tumors through PET/CT scanning, facilitating a theranostic approach when paired with FRα-targeted therapies such as antibody-drug conjugates (e.g., EMP505).

Other names: EMP502-Dx-Empiriko-FRα-diagnostic radiotracer (RCV + 68Ga)-Ovarian Cancer

Targets

FOLR1 (FRα)

Beyond the preview

Go deeper on EMP502-Dx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMP502-Dx.

Explore the full profile